Clinician-led · Australian-formulated · TGA Schedule 4

Zero THC.
Zero Compromise.

100% THC-FREE · CBD ISOLATE

The prescription wellbeing program for Australians who get drug-tested. No THC. No impairment. No positive roadside or workplace screens. WADA-permitted. The performance edge you can actually pass a test on.

Speak to a clinician How it works
Scroll
No psychoactive THC
THC-Free
Roadside AS 4760
Driver-Safe
Workplace AS/NZS 4308
Worksite-Safe
Off the prohibited list
WADA-Permitted
Zero THCDriver-SafeWorkplace-SafeWADA-PermittedAustralian MadePrescription OnlyClinician LedZero THCDriver-SafeWorkplace-SafeWADA-PermittedAustralian MadePrescription OnlyClinician Led
/ Our position

Made in Australia.

Prescribed by Australian doctors.

For Australian patients.

Standards you can trust—

without compromise.

/ The system

Two products.One protocol.

/ The lineup

Day & Night.

Daytime

Charge

Clinically formulated · Australian made

  • Daytime focus & calm — zero THC
  • Novel delivery — superior bioavailability
  • Clinician-prescribed via TGA SAS
  • Manufactured in Australia
  • WADA-permitted · driver & workplace safe
Nightly

Recharge

Clinically formulated · Australian made

  • Nightly recovery & sleep — zero THC
  • Novel delivery — superior bioavailability
  • Clinician-prescribed via TGA SAS
  • Manufactured in Australia
  • WADA-permitted · driver & workplace safe
/ Sovereign supply

Made here. Held here.

Australian medicinal cannabis sits inside one of the most rigorous regulatory frameworks in the world — and 2032CBD is built to operate at every link in that chain. Formulated by Australian clinicians. Manufactured under Australian standards. Dispensed by Australian pharmacists. Prescribed by Australian doctors.

01Formulated here

A program designed by Australian medical practitioners to address Australian patient needs — under the oversight of the Therapeutic Goods Administration.

02Manufactured here

Production occurs within an Australian compounding pharmacy environment, with a path to GMP-grade manufacturing as the program scales.

03Dispensed here

Every prescription is filled by a registered Australian pharmacy with full chain-of-custody traceability from formulation to patient.

/ Compliance posture

Three frameworks.
One product.

Pathway 01

TGA SAS

Schedule 4 prescription medicine accessed via the Therapeutic Goods Administration's Special Access Scheme. Every dispense is clinician-authorised and traceable.

Prescription-only · Fully traceable · Clinician-gated
Pathway 02

WADA Compliant

Formulated to align with the World Anti-Doping Agency standard for permitted substances. For Australians whose livelihood — or licence — depends on what's in their system.

For those who get tested · Periodically retested · Auditable
Pathway 03

Workplace & Roadside

Designed to be compatible with workplace drug-screening protocols and roadside oral-fluid testing — for FIFO, defence, professional drivers, healthcare and parents on the school run.

Workplace screen-friendly · Driver-test friendly · Reviewed quarterly

Don't take our word for it. Take the certification.

/ The difference

Most medicinal cannabis
contains THC. Ours doesn't.

Australia has 500+ medicinal cannabis products. The overwhelming majority contain THC — the psychoactive compound that shows up on roadside and workplace drug tests, and that sits on the WADA Prohibited List. For a huge group of Australians, that's a non-starter. 2032CBD was built specifically for them.

Typical THC product
  • ✕ Contains THC — psychoactive & impairing
  • ✕ Positive roadside oral-fluid test
  • ✕ Positive workplace drug screen
  • ✕ Prohibited in-competition by WADA
  • ✕ Can't drive after dosing
  • ✕ Off-limits for FIFO, defence, drivers, pilots
2032CBD
  • ✓ CBD isolate — zero THC, zero impairment
  • ✓ Won't trigger roadside testing (AS 4760)
  • ✓ Won't trigger workplace testing (AS/NZS 4308)
  • ✓ CBD removed from WADA list since 2018
  • ✓ Clear-headed, fully functional, day or night
  • ✓ Built for safety-critical occupations

If your job, your licence or your sport depends on a clean test, the THC question isn't a preference — it's a dealbreaker. We removed it from the equation.

/ The pathway

From enquiry to prescription.

/ STEP 01

Enquire & onboard

Submit an interest form. Receive a unique secure login. Complete your profile, baseline survey and consent online — privately and at your own pace.

/ STEP 02

Clinician consult

Once onboarding is complete, our clinical team contacts you to schedule a consultation with the prescribing physician — in person or via telehealth.

/ STEP 03

Prescription & dispense

If clinically appropriate, your prescription is sent to our partner Australian pharmacy. Your supply is dispensed and delivered, or available for in-clinic collection.

/ STEP 04

Ongoing care

Track your progress through the patient portal. Two-way messaging with the clinical team. Scheduled reviews. Continued supply only with clinician approval.

Dr Saul Geffen, Clinical Lead
/ Clinical lead

Dr Saul Geffen

Pain & Rehabilitation Medicine Specialist

Dr Saul Geffen is a fellow of the Faculty of Pain Medicine and brings over two decades of specialist practice in chronic pain, rehabilitation and recovery medicine. He leads the clinical program for 2032CBD — overseeing patient assessment, prescribing protocols, formulation review and adverse-event monitoring.

The 2032CBD program is built around his clinical philosophy: that medicinal cannabis access in Australia must be evidence-driven, conservatively dosed, and properly supervised — not a replacement for primary care, but a complement to it.

"Australians deserve a prescription pathway that's clinically supervised, locally regulated, and built for people who can't afford to compromise on what they put in their body."
/ Get in touch

Take the next step.

Three ways to engage with the 2032CBD program. Pick the path that matches where you're at.

Pain
Sleep
Anxiety
Recovery
Focus
Stress
Inflammation
General wellbeing
I consent to 2032CBD storing this information to respond to my enquiry. No medical advice is being provided through this form. Privacy policy applies.
Pain
Sleep
Anxiety
Recovery
Focus
Stress
Inflammation
Other
WADA-tested
Workplace drug-tested
Professional driver / roadside-tested
Defence / safety-critical role
None of these
I consent to 2032CBD contacting me about access to the program. I understand any prescription decision is at the discretion of the consulting clinician. Privacy policy applies.
I am a registered Australian healthcare practitioner. I consent to receiving prescriber-targeted information about the 2032CBD program.

Got it.

Your enquiry is in. The clinical team will be in touch via your preferred contact channel within two business days.

Need to follow up? Email us directly at hello@2032cbd.com.au

Or email us directly at hello@2032cbd.com.au

/ Regulatory framework

How prescription access works.

/ FRAMEWORK 01

Schedule 4 medicine

2032CBD is a Schedule 4 prescription medicine under the Therapeutic Goods Act. It is not available over the counter. Access is gated through registered Australian medical practitioners.

/ FRAMEWORK 02

Special Access Scheme

Prescriptions are issued under the TGA's SAS-B pathway, which permits Australian doctors to prescribe specific unapproved therapeutic goods to individual patients for whom the medicine is clinically indicated.

/ FRAMEWORK 03

Pharmacy dispensed

Every prescription is dispensed by a registered Australian pharmacy under the supervision of a pharmacist. Each batch carries a Certificate of Analysis viewable by your clinician.

Portal access.

/ For patients

Patient Login

Profile, baseline survey, consent, daily check-ins, surveys, batch certificates, two-way messaging with the clinical team.

Sign in →
/ For clinicians

Clinician Login

Patient cohort overview, pending bookings, outcomes analytics, batch QA, formulation panel, lead pipeline, adverse-event log, prescriber documentation.

Sign in →